EMA Authorised: Zirabev (bevacizumab) — Pfizer Europe MA EEIG

View source ↗

Summary

Zirabev (bevacizumab) has been authorised by EMA for multiple cancer indications, including colorectal, breast, non-small cell lung, renal cell, and cervical ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Colorectal Cancer
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• ZIRABEV (BEVACIZUMAB-BVZR)

Snippet

Status: Authorised. Therapeutic area: Colorectal Neoplasms;Breast Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms. MAH: Pfizer Europe MA EEIG. Decision date: 25/03/2026